Semaglutide
Glucose control · Weight management · Cardiovascular benefits
Semaglutide the active ingredient in Wegovy and Ozempic, was initially developed to assist diabetic patients in managing their blood sugar levels. However, it has unveiled an unexpected benefit: significant weight reduction. This remarkable discovery prompted extensive research into Semaglutide’s potential as a weight loss medication. The FDA’s approval of Semaglutide, marketed as Wegovy, as a weight loss medication in June 2021 signifies a major breakthrough in the field.
Glucose control
Semaglutide helps to lower blood sugar levels by increasing insulin secretion and reducing glucagon production. This leads to better glucose management in individuals with type 2 diabetes.
Weight management
Semaglutide has been shown to aid in weight loss. Clinical studies have demonstrated that semaglutide can lead to significant reductions in body weight, making it beneficial for individuals who have obesity or struggle with weight management.
Cardiovascular benefits
Semaglutide has been found to have cardiovascular benefits in clinical trials. It has been associated with a reduced risk of major adverse cardiovascular events in people with type 2 diabetes and established cardiovascular disease.
How Does Semaglutide Work?
Semaglutide operates by imitating glucagon-like peptide-1 (GLP-1), a hormone that regulates appetite and affects various bodily processes. By targeting the appetite-regulating area of the brain, semaglutide acts as a potent appetite suppressant. It also enhances insulin production and inhibits the production of glucagon, a hormone that raises blood sugar levels. Additionally, semaglutide produces several physiological effects, such as delaying stomach emptying, reducing gastrointestinal muscle contractions, and lowering blood sugar levels. It also stimulates insulin secretion by the pancreas. Participants who received weekly Semaglutide injections witnessed a remarkable average weight loss of 15.3%, surpassing the placebo group’s mere 2.6%. This groundbreaking evidence led to the FDA’s endorsement of Semaglutide as Wegovy, an FDA-approved long-term weight loss medication.
Approval is done by a one time telemed appointment with a medical provider licensed in South Dakota. This can be completed with us or at your own home.